Should I buy or sell Pardes Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares. View PRDS analyst ratings or view top-rated stocks .

NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PRDS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.16
▼
$2.16
50-Day Range: $2.13
▼
$2.16
52-Week Range: $0.75
▼
$3.93

Volume: 400 shs
Average Volume: 359,530 shs
Market Capitalization: $133.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Pardes Biosciences alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Pardes Biosciences Stock (NASDAQ:PRDS)

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

PRDS Stock News Headlines

October 31, 2023 | yahoo.com

Pardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo Weather

August 31, 2023 | finance.yahoo.com

Pardes Biosciences Announces Closing of Tender Offer

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 28, 2023 | finance.yahoo.com

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

August 17, 2023 | finance.yahoo.com

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

August 3, 2023 | msn.com

Pardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28

July 19, 2023 | marketwatch.com

Pardes Biosciences Shares Rise 15% After Buyout Offer From MediPacific

July 19, 2023 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

July 18, 2023 | msn.com

JMP Securities Downgrades Pardes Biosciences (PRDS)

July 17, 2023 | benzinga.com

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

July 17, 2023 | msn.com

Pardes Biosciences stock rallies on buyout offer from MediPacific

July 17, 2023 | benzinga.com

Why Pardes Biosciences Shares Are Rising Monday

July 17, 2023 | markets.businessinsider.com

Pardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-market

July 17, 2023 | finance.yahoo.com

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

June 5, 2023 | finance.yahoo.com

All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy

May 17, 2023 | seekingalpha.com

Pardes Biosciences Seeking Strategic Alternatives

May 9, 2023 | markets.businessinsider.com

Pardes Biosciences (PRDS) Receives a Hold from SVB Securities

May 6, 2023 | barrons.com

Pardes Biosciences Inc.

May 6, 2023 | finanznachrichten.de

Pardes Biosciences, Inc: Pardes Biosciences Reports First Quarter 2023 Financial Results

May 5, 2023 | msn.com

Recap: Pardes Biosciences Q1 Earnings

May 5, 2023 | finance.yahoo.com

Pardes Biosciences Reports First Quarter 2023 Financial Results

April 12, 2023 | benzinga.com

Analyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?

April 7, 2023 | seekingalpha.com

Pardes Biosciences cut at Jefferies on COVID drug failure

April 4, 2023 | msn.com

SVB Leerink Downgrades FS Development Corp II (PRDS)

April 4, 2023 | markets.businessinsider.com

SVB Securities downgrades Pardes Biosciences (PRDS) to a Hold

April 3, 2023 | msn.com

Pardes slumps ~10% after COVID drug trial failure prompts strategic review

See More Headlines

Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:PRDS
CUSIP: N/A
CIK: 1822711
Web: www.pardesbio.com
Phone: 415-649-8758
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -43.36%
Return on Assets: -40.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 81.72
Quick Ratio: 81.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.51 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 62,012,000
Free Float: 36,711,000
Market Cap: $133.95 million
Optionable: Not Optionable
Beta: 0.42

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Thomas G. Wiggans (Age 71)
CEO & Chairman
Comp: $859.4k
Dr. Uri A. Lopatin M.D. (Age 51)
Founder & Director
Comp: $786.96k
Ms. Heidi Henson CPA (Age 57)
Chief Financial Officer
Comp: $564.6k
Ms. Elizabeth Haber Lacy J.D. (Age 56)
Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

PRDS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pardes Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares.
View PRDS analyst ratings or view top-rated stocks.

This page (NASDAQ:PRDS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pardes Biosciences (PRDS) Stock Price, News & Analysis

About Pardes Biosciences Stock (NASDAQ:PRDS)

PRDS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PRDS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info